Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
doi: 10.1083/jcb.202105043 60 LiuJKangRTangD
The aims of this review are (1) to provide an overview of the clinical and biological overlap between neuropsychiatric long COVID and other fatigue-associated neuropsychiatric disorders, (2) to examine the shared molecular mechanisms of fatigue and depressive symptoms involving acetylcarnitine metabolism, and finally (3) to review the current evidence on acetylcarnitine supplementation studies as a treatment for fatigue-associated syndromes and pharmacological aspects of acetylcarnitine supplementation to provide a conceptual foundation for acetylcarnitine supplementation in neuropsychiatric long COVID syndrome
The difference is what else is in the formulation
March 1, 2024
